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Abstract 
Until now medical prescription of diamorphine (heroin) has been suggested to be suitable for 
patients who have failed previous maintenance treatments. The German project of heroin 
assisted treatment of opiate dependent patients compared diamorphine versus methadone 
maintenance treatment and included 107 patients with no previous maintenance treatment 
experience (NPME). When comparing this subsample with the rest of the participants of the 
study, large baseline differences were found, showing a more severe drug use profile in those 
without maintenance experience. However, no differences were found in treatment outcome 
or treatment retention. In the subsample of NPME, outcome measures on the reduction of 
illicit drug use were significantly better under diamorphine treatment compared to methadone 
treatment, while health outcome showed no difference. The results imply that diamorphine 
treatment could be considered as one of several options in treating severely opioid dependent 
patients, regardless of previous maintenance treatment experience. 
Keywords 
Previous maintenance treatment, diamorphine, heroin-assisted treatment, methadone 
maintenance, opioid dependence. 
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1. Introduction 
As opioid dependence is a chronic relapsing disorder, agonist maintenance treatment is 
considered the first line of treatment [1]. Methadone is the most extensively studied and most 
widely used substance in maintenance treatment, and is therefore considered the first choice 
maintenance treatment in most countries [2-4]. Although less effective, buprenorphine is also 
considered an alternative medication as a first choice maintenance treatment [5-7]. Finally, 
slow release oral morphine seems to be a promising treatment and is used as first choice in 
some countries [8]. 
A rather new development is the medical prescription of diamorphine (heroin) to chronic, 
treatment refractory heroin dependent patients. This intervention that has been tested in a 
variety of countries in Europe and North America [9], and further studies are currently 
underway. Medical prescription of heroin (Heroin Assisted Treatment, HAT) has been found 
to be more effective than methadone for chronic, treatment refractory heroin-dependent 
patients [10-13].  
Until now all trials have included only patients with previous experience in maintenance 
treatment. The Swiss National Cohort study included as admission criteria at least two 
previous maintenance treatment attempts without satisfactory results [14]. Previous 
experience in Methadone Maintenance Treatment (MMT) in the last six months was a 
necessary inclusion criteria in the Dutch randomised controlled trials, where HAT was 
designed to be an add-on treatment to MMT [11]. Inclusion in the Spanish controlled trial 
necessitated two previous MMT treatment attempts [12]. The Canadian study required at least 
one previous episode of maintenance treatment with an adequate dose for at least 30 days 
[15]. Inclusion in the ongoing British Randomised Injecting Opioid Treatment Trial requires 
previous effective MMT for an extended period of time [16]. The recently initiated Belgian 
HAT trial also requires patients to have had two failed attempts of MMT or to presently be a 
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non-responder in MMT [17]. Previous abstinence-based treatment was found to be a predictor 
of effectiveness in the Dutch study [18], but no other influence of previous treatment 
experience on outcome measures has been reported in other trials. 
In contrast to these studies, the German heroin trial required patients to be non-responders in 
MMT or to have undergone two unsuccessful previous addiction treatment attempts (mainly 
maintenance, but also outpatient or inpatient abstinence-based treatment [19]). Therefore, 
patients could be included with two previous unsuccessful treatment attempts in abstinence-
based programmes without previous maintenance treatment experience. The aim of this study 
is to assess the efficacy of diamorphine versus methadone treatment for patients with no 
previous maintenance treatment experience. 
 
2. Methods 
2.1 The German heroin trial 
In a randomized controlled trial, HAT and MMT was compared in a multicenter study among 
1015 patients in 7 cities in Germany. This intent to treat sample was the result of a 
randomisation of 1032 heroin addicted patients fulfilling inclusion criteria and attending 
examination from a previous screening of 2038 patients. Recruitment was stratified from two 
target groups: 1. methadone non-responders, and 2. patients not in treatment for the last 6 
months but with two previous treatment attempts (either abstinence-based or maintenance; see 
Haasen et al. 2007 for details). Patients were randomised into four subgroups depending on 
type of treatment (HAT or MMT) and psychosocial care received (psychoeducation plus 
individual counselling or case management plus motivational interviewing). Heroin or 
methadone was dispensed over 12 months. HAT patients received an individually adjusted 
maximum of three doses of intravenous diamorphine (heroin) per day with an additional 
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(maximum of) 60 mg oral methadone when needed, while MMT patients received one 
individually adjusted single dose of oral methadone daily. Long term effects have been 
analysed for HAT patients who continued in treatment for another 12 months [20]. 
 
2.2 Measures 
Information used in this study included: (1) Self-reported information on drug use and 
criminal activity according to the EuropASI [21], based on the fifth edition of the Addiction 
Severity Index [22]; German version: [23]. (2) Psychopathology, measured with the health 
scale and Global Severity Index (GSI) of the Symptom Checklist-90-Revised (SCL-90-R, 
[24]). (3) Health status measured with the Opiate Treatment Index Health-Symptoms-Scale 
[25]. (4) Urine samples for heroin and cocaine use. (5) Mental and physical health 
improvement as well as reduction of illicit drug use (difference between baseline and 12 
months) was used to determine dichotomous outcome measures (see Haasen et al. [13] for 
details). 
 
2.3 Subjects 
To carry out this study the ITT sample (N=1015) was divided into two subsamples: patients 
with previous maintenance treatment experience (PME, n=899) and patients without (NPME, 
n=107). Nine patients were not included in the analysis due to missing data on previous 
maintenance treatment. 
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2.4 Statistical analysis 
Baseline characteristics were compared using t-tests for continuous variables and Chi square 
tests for nominal variables between patients in HAT or MMT and subsamples with or without 
previous maintenance treatment experience (PME or NPME). As noted in the previous 
publication [13], this trial demonstrated the higher effect of HAT on treatment outcomes 
without influence of other factors such as target group (methadone treatment failures versus 
not in treatment), type of psychosocial intervention (psychoeducation versus case 
management) and study site. Therefore, a two-factorial logistic regression model was used to 
assess the possible effect of previous maintenance treatment only controlling for type of 
medication. Additionally, Chi square and Odds ratio were calculated separately in the PME 
and NPME subsamples in order to assess the differential effect of the type of medication on 
outcome measures. A one factor ANCOVA was carried out in the NPME subsample between 
treatment groups for illegal activities in the last 30 days at end of treatment controlling for 
baseline data. The confidence interval was set up at 95%. Analyses were made using SPSS 
version 15 for Windows. 
3. Results 
3.1 Participant characteristics 
Table 1 shows baseline characteristics of the participants. Between the two medication groups 
in the subsample without maintenance treatment experience (NPME), there was only one 
significant difference with HAT patients having a higher proportion of hepatitis C infections 
(2=7.308, p=.007). 
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Table 1: Baseline characteristics of the 107 participants who didn’t have a previous maintenance treatment and the rest of the sample. 
 NPME subsample Rest of the sample 
(PME) 
 
 HAT (n=59) MMT(n=48) Total (n=107) Significance HAT 
vs. MMT 
(n=899) Significance NPME 
vs. PME 
Male (n, %) 53, 89.8 43, 89.6 96, 89.7 n.s. 709, 78.9 ** 
Age (years) 34.37±6.57 35.75±6.81 34.99±6.68 n.s. 36.55±6.67 * 
Stable housing (n, %) 38, 64.4 24, 51.1 62, 58.5 n.s. 635, 70.9 ** 
Employed (n, %) 4, 6.8 7, 14.9 11,10.4 n.s. 120, 13.4 n.s. 
Regular drug use (years):       
 Heroin 10.19±5.16 11.88±5.68 10.94±5.44 n.s. 13.95±6.33 *** 
 Cocaine 4.78±6.41 4.02±4.73 4.44±5.71 n.s. 5.70±6.59 * 
 Benzodiazepines 2.92±4.71 1.83±3.93 2.43±4.39 n.s. 5.56±7.19 *** 
Drug use in past month a):       
 Heroin (days) 27.95±4.89 28.74±3.91 28.30±4.48 n.s. 21.29±10.37 *** 
 Cocaine (n, %) 44, 74.6 31, 66.0 75, 70.8 n.s. 657, 73.2 n.s. 
 Cocaine (days) 8.05±10.36 10.58±12.76 9.09±11.40 n.s. 7.49±9.93 n.s. 
 Benzodiazepines (n, %) 33, 55.9 19, 40.4 52, 49.1 n.s. 519, 57.9 n.s. 
 Benzodiazepines (days) 9.27±10.24 12.89±11.75 10.60±10.85 n.s. 16.85±11.51 *** 
 Intravenous drug use (n, %) 58, 98.3 47, 100.0 105, 99.1 n.s. 855, 95.6 n.s. 
 Intravenous drug use (days) 27.16±6.6 27.43±5.8 27.28±6.23 n.s. 22.95±9.80 *** 
Alcohol use (n, %) 33, 56.9 23, 48.9 56, 53.3 n.s. 532, 59.4 n.s. 
Alcohol use in past month (days) 14,64±11,19 14,83±12,73 14,71±11,74 n.s. 17,02±11,85 n.s 
Previous detox treatment (n, %) 49, 83.1 36, 75.0 85, 79.4 n.s. 794, 89.4 ** 
Previous drug free treatment (n, 
%) 
29, 49.2 20, 41.7 49, 45.8 n.s. 571, 65.7 *** 
Physical health:       
 OTI health scale (0-50 pts) 17.78±4.81 19.48±4.40 18.54±4.69 
 
n.s. 18.99±5.36 n.s. 
 Body mass index (BMI) 22.59±3.54 22.08±3.15 22.36±3.36 n.s. 22.67±3.51 n.s. 
 HIV positive (n, %) 3, 5.3 2, 4.2 5,  4.7 n.s. 85, 9.5 n.s. 
 HCV positive (n, %) 45,79.0 26, 54.2 71,  67.6 ** 740, 83.0 *** 
Mental health:       
 GSI (standardised T-score) 66.92±10.89 69.10±10.47 67,90±10,71 n.s. 69.52±10.30 n.s. 
 Previous suicide attempts (n, 
%) 
11, 20.0 11,22.9 22,  20.6 n.s. 340, 38.9 *** 
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Social functioning:       
 GAFS (0-100)b) 55.92±13.37 55.50±10.77 55.73±12.22 n.s. 53.36±11.45 * 
 Illegal activities past month 
(days) 
16.64±13.27 17.67±12.57 17.09±12.91 n.s. 15,07±12,84 n.s. 
 Ever convicted (n, %) 55, 96.5 45, 95.7 100, 96.2 n.s. 847, 96.3 n.s. 
 Ever incarcerated (n, %) 44, 74.6 29,69.1 73, 72.3 n.s. 649, 74.9 n.s. 
 
* p <.05 
** p <.01 
*** p <.001 
n.s. nonsignificant 
HAT: Heroin Assisted Treatment 
MMT: Methadone Maintenance Treatment 
NPME: Participants with no previous maintenance treatment experience. 
PME: Rest of the sample (Participants with previous maintenance treatment experience). 
a) The mean days of consume were calculated only in patients who had at least one day of consume. 
b) Global Assessment of Functioning Scale. 
 
Table 2.  Effectiveness of heroin versus methadone treatment on primary outcome measures (POM). 
 NPME     PME     
 HAT  MMT  Significance HAT vs. MMT HAT  MMT  Significance HAT vs. MMT 
 N % N %  N % N %  
Response POM Health 46 78.0 39 81.3 OR=.817, 95%-CI: .315-2.113;  2=0.175, 
p=.676 
363 80.1 327 73.3 OR=1.468, 95%-CI: 1.074-2.005;  
2=5.848, p=.016 
Response POM Illegal 
drug use 
46 78.0 19 39.6 
OR=5.401, 95%-CI: 2.320-12.570, 
2=16.353, p<0.0001 
309 68.2 253 45.0 OR=1.673, 95%-CI: 1.247-2.149, 
2=12.651, p<0.0001 
Response both POM 
38 64.4 15 31.6 OR=3.981, 95%-CI: 1.770-8.951, 
2=9.187, p<0.005 
256 56.5 207 46.4 OR=1.500, 95%-CI: 1.153-1.952, 
2=9.178, p<0.005 
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Compared to patients with previous maintenance treatment experience (PME) at baseline, 
NPME patients included less females (2=7,046, p=.008), were younger (t=2.292, p=.022), 
had a poorer housing situation (2=6.861, p=.009), had less experience with detoxification 
(2=9.266, p=.002) and drug free treatment (2=16.304, p<.0001), had fewer years of heroin 
use (t=5.306, p<.0001), cocaine use (t=1.888, p=.059) and benzodiazepine use (t=6.402, 
p<.0001), and more days of heroin use in the last month (t=-12.497, p<.0001). They also had 
injected drugs (t=-6.224, p<.0001) and consumed benzodiazepines (t=3.939, p<.0001) on 
more days in the last month, but the proportion of HCV infected was lower (2=14.586, 
p<.0001), which corresponds to fewer years of heroin use.. Finally, those in the NPME 
subsample had a lower rate of suicide attempts (2=12.102, p=.001) and a higher score in the 
Global Assessment of Functioning Scale (t=-2.008, p=.045). 
 
3.2 Treatment retention 
Treatment retention for NPME (53.84%) did not differ from PME patients (53.27%). In 
contrast with the results of the main study, no significant differences were found in treatment 
retention between HAT and MMT in the NPME subsample (HAT: 55.93%, MMT: 50.00% 
(2=.374, n.s.). No significant differences were found in treatment duration between HAT 
(276 days) and MMT (244 days) groups in the NPME subsample (t=1.12, n.s.). The mean 
daily dose of diamorphine was 401.90 mg (range: 15.00-710.30, SD= 177.84) with an 
additional 8.50 mg (range: 0.26-41.18, SD= 9.94) of methadone over all heroin treatment 
days. In the methadone group the mean daily dose was 87.35 (range: 36.03-165.62, 
SD=37.61). Compared to PME patients, no significant differences in dosage were found. 
 
3.3 Treatment effectiveness 
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The two-factorial logistic regression model analysis showed no influence of previous 
maintenance treatment experience on primary outcome measures (POM) health, illegal drug 
use or both when analyzing for treatment group. When analyzing subsamples separately, no 
influence of treatment was found in NPME patients on health in contrast with PME patients, 
but a significantly greater response for HAT patients was found in the POM illicit drug use 
and for response in both outcome measures (see table 2). With respect to the outcome 
measure of reduction of illegal activity, the subsample of patients without previous 
maintenance treatment experience showed no difference at baseline between the HAT and 
MMT groups (see table 1), but after 12 months illegal activity reduced to 0.81 days (of the 
last 30 days) in the HAT group as compared to 5.56 days in the MMT group (ANCOVA: 
F=10.120, p=.002). 
Figure 1 shows the course of health indicators. Physical health (as measured with the OTI 
Health-Symptoms-Scale) showed an overall high improvement in the first phase of the study. 
A slight deterioration for MMT patients can be perceived in the last 6 months of the study, 
while HAT patients continued to show a stable amelioration. Mental health (as measured with 
the GSI of the SCL-90-R) showed a parallel course in both subgroups. While HAT patients 
had a better outcome in the first 3 months, at 6 months both groups showed similar results. 
Towards the end of the study, MMT patients slightly worsened while stable effects were 
found in the HAT group.  
Figure 2 shows the course of street heroin and cocaine use according to self-reported data. 
Although both groups reduced the use of illicit heroin, higher reduction can be seen in the 
HAT group. Cocaine use reduction was steady for HAT patients, while MMT patients only 
showed a reduction of cocaine use in the first few months. These results were confirmed by 
the urine samples taken in the course of the study (figure 3). The percentage of cocaine 
positive urines during treatment was 32.2% for HAT and 38.9% for MMT patients.
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Figure 1: Assessment of health according to OTI health scale (left) and Global Severity Index (GSI) of the SCL-90-Ra) (right) during the study 
period in the subsample of patients without maintenance treatment experience b) 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) At T0 the SCL-90-R was not assessed, in order to avoid overlap artefacts, since the SCL-90-R measures symptoms occurring in the last 7 days. 
b) OTI-HSS: N-1=107, N0=94, N1=89, N3=82, N6=81, N12=101, SCL-90-R: N-1=107, N1=89, N3=81, N6=81, N12=101. 
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Figure 2: Change in street heroin use (left) and cocaine use (right) in the subsample of patients without maintenance treatment experience a) 
 
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) Self-reported data of use in the last 30 days, street heroin: N-1=107, N0=95, N1=88, N3=82, N6=85, N12=103, cocaine: N-1=107, N0=95, N1=88, N3=82, N6=85, N12=103. 
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Figure 3: Urine samplesa) testing for street heroin (left) and cocaine (right) in the subsample of patients without maintenance treatment experience 
 
 
 
   
 
  
 
 
 
 
 
 
 
 
 
 
 
a) Urine samples for street heroin (N=51-101) in the 5 weeks prior to T6 (W22 – W26) and T12 (W48 – W52) and weekly urine samples for cocaine (N=51-10) 
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Discussion 
Heroin assisted treatment (HAT) has been considered a second- or last-choice 
intervention. This consideration largely rests on four facts: First, injecting bears higher 
health risks than oral treatment, so that maintenance treatment is suggested to be 
initiated with an oral substance. Second, injecting a substance is thought to maintain the 
craving aspects of addiction, which could be avoided by an oral substance. Third, the 
psychoactive central-nervous effect of diamorphine also upholds craving, which is 
considered problematic in the long-term treatment of an addictive disorder. Finally, 
HAT is more expensive than MMT and necessitates more resources. On the other hand 
HAT might have an advantage in including patients in treatment that would otherwise 
choose not to enter maintenance treatment at all. If this was the case, it would be 
necessary to evaluate whether HAT is just as effective as MMT for chronic opioid 
dependent patients. 
The present study is the first to analyse the effect of HAT in patients without previous 
maintenance treatment experience. The results show that patients without previous 
maintenance treatment experience, who have a shorter addiction career, benefit from 
both HAT and MMT to almost the same extent than those with maintenance treatment 
experience. The most important and surprising finding is the superiority of HAT in this 
subsample, considering the fact that unlike the rest of the sample, they have had no 
previous (negative) experience with MMT. This superiority was not found in all 
outcome measures. While no difference was found in the primary outcome measure on 
health, a significant difference became apparent in the reduction of illicit drug use and 
the reduction of illegal activity, which are generally considered two main goals of 
maintenance treatment. 
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These findings cannot be explained with a higher drop-out rate in the MMT group, as 
the retention rates did not differ in the two treatment groups of patients without previous 
maintenance treatment experience. Nonetheless, the 107 patients entered the study with 
the intention of possibly being randomised into the diamorphine group. Even those 
patients randomised into the methadone group had the possibility of switching into the 
diamorphine group after completing one year of methadone maintenance, so that the 
attractiveness of HAT may still have played an important role in drawing these patients 
into maintenance treatment, a path which they previously had not chosen to follow 
despite the low threshold to entry into maintenance treatment in Germany.  
These results therefore should lead us to reconsider whether HAT should only be 
implemented as a second line treatment, or whether it should be made available for all 
chronic severely opioid dependent patients. However, this study was self-selective and 
did not control for the factor of previous maintenance treatment experience in an 
experimental design. Therefore in the future it would be necessary to confirm our results 
in a controlled trial, as this would have important implications for the scope of this 
innovative treatment option.  
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